Patient Education
Enhanced External Counterpulsation (EECP) is a non-invasive, FDA-cleared treatment for heart disease that uses pneumatic cuffs on the legs to improve blood flow to the heart — with no surgery, no catheters, and no hospital stay.
During an EECP session, you lie on a padded treatment table while three sets of pneumatic cuffs are wrapped around your calves, thighs, and buttocks. These cuffs are connected to a computer that monitors your heart rhythm via ECG.
The cuffs inflate rapidly during diastole — the resting phase between heartbeats — squeezing blood from the legs upward toward the heart. This increases the pressure of blood returning to the coronary arteries, improving oxygen delivery to heart muscle. The cuffs then deflate instantly at the start of systole (the pumping phase), reducing the resistance the heart must pump against.
Over a full course of 35 sessions, this repeated mechanical stimulus triggers the growth of new collateral blood vessels around blocked coronary arteries — a process called angiogenesis. It also increases the production of nitric oxide, which relaxes and dilates blood vessels, and improves endothelial function throughout the cardiovascular system.
The net effect is a heart that receives more blood, pumps more efficiently, and is surrounded by a richer network of collateral vessels — often described as a "natural bypass."
Off-label use is legal and common in medicine. The following conditions have published case reports, observational studies, or pilot trials supporting EECP's potential benefit:
One hour long. You lie on a padded table, fully clothed from the waist up. Cuffs are applied to your legs. Most patients read, watch TV, or rest during treatment.
35 sessions total. Standard schedule is 5 days/week for 7 weeks. Accelerated schedules (2 sessions/day, 7 days/week) can complete the course in 18 days.
Most patients notice improvement in angina symptoms, exercise capacity, and energy within the first 15–20 sessions. Benefits typically last 3–5 years.
EECP has been studied in randomized controlled trials, large patient registries, and mechanistic research since the 1990s.
Journal of the American College of Cardiology
Multicenter randomized controlled trial demonstrating significant reduction in angina episodes and improved exercise tolerance in patients with chronic stable angina.
American Journal of Cardiology
Registry of over 5,000 patients showing 75–80% of patients with refractory angina reported sustained improvement in symptoms after EECP treatment.
Congestive Heart Failure
Study demonstrating improvements in exercise capacity, quality of life, and NYHA functional class in patients with chronic heart failure following EECP.
Circulation
Research showing EECP promotes collateral vessel development and increases nitric oxide production, providing a mechanistic explanation for its clinical benefits.
EECPLocator.com is the independent directory of 139 verified EECP providers across 35 US states — graded on indication breadth, clinical posture, and early-use philosophy.